2023 / 01

Next Paper
DOI: 10.47183/mes.2023.003

ORIGINAL RESEARCH

Clinical and virological characteristics of chronic hepatitis B and response to antiviral therapy

Nguyen Thi-Hanh1, Melnikova LI2, Ilchenko LYu1,3, Kyuregyan KK4, Gordeychuk IV3, Bondarenko NL2
About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Clinical Hospital № 85 of Federal Medical-Biological Agency, Moscow, Russia

3 Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products, Moscow, Russia

4 Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

Correspondence should be addressed: Nguyen Thi-Hanh
Akademika Volgina, 39, Moscow, 117437, Russia; ur.liam@hnahrd

About paper

Author contribution: Nguyen Thi-Hanh — sample collection, data analysis, manuscript writing; Melnikova LI — sample collection, data analysis; Ilchenko LYu — study design, data analysis, manuscript editing; Kyuregyan KK — literature review; Gordeychuk IV — data analysis; Bondarenko NL — editing and approval of the final version of the article.

Compliance with ethical standards: the study was approved by the Ethics Committee of Pirogov Russian National Research Medical University (protocol № 213 of 13 December 2021).

Received: 2022-12-08 Accepted: 2023-02-17 Published online: 2023-03-05
|
  1. World Health Organization. Hepatitis B Fact Sheet. July 27, 2020.
  2. Ministerstvo zdravooxraneniya Rossijskoj Federacii. Xronicheskij virusnyj gepatit B (XVGV) u vzroslyx. 2019. Russian.
  3. Pokrovskij VI, Totolyan AA, Ehsaulenko EV, Suxoruk AA. Virusnye gepatity v Rossijskoj Federacii: Analiticheskij obzor. 11 vypusk. SPb.: FBUN NIIEhM imeni Pastera, 2018. Russian.
  4. O sostoyanii sanitarno-ehpidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2020 godu: Federal'naya sluzhba po nadzoru v sfere zashhity prav potrebitelej i blagopoluchiya cheloveka. 2021. Russian.
  5. European Association For The Study Of The Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. 2017; 67 (2): 370–98.
  6. Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology. 2000; 118 (2): S83–S103.
  7. Ivashkin VT, Yushhuk ND, Maevskaya MV, Znojko OO, Dudina KR, Karetkina GN, i dr. Klinicheskie rekomendacii Rossijskoj gastroehnterologicheskoj associacii i Rossijskogo obshhestva po izucheniyu pecheni po diagnostike i lecheniyu vzroslyx bol'nyx gepatitom B. Rossijskij zhurnal gastroehnterologii, gepatologii, koloproktologii. 2014; 3: 58–88. Russian.
  8. Panevkina S, Abduraxmanov D, Ibragimov Eh, Rozina T, Nikulkina E, Tanashhuk E, i dr. Ocenka fibroza pecheni pri dlitel'noj terapii xronicheskogo gepatita V nukleozidnymi i nukleotidnymi analogami. Terapiya. 2021; 7 (6): 24–31. Russian.
  9. Orlov SG, Myazin AE, Chulanov VP, redaktory. Rasprostranennost' genotipov virusa gepatita V sredi lic, xronicheski inficirovannyx virusom gepatita V v Moskve i Moskovskoj oblasti. Materialy Rossijskoj nauchno-prakticheskoj konferencii «Genodiagnostika infekcionnyx boleznej» 25–27 oktyabrya 2005 g. Sosnovka, Novosibirskaya obl. 2005; 56 s. Russian.
  10. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Long-term continuous entecavir therapy in nucleos (t) ide-naïve chronic hepatitis B patients. Journal of hepatology. 2012; 57 (3): 508–14.
  11. Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, et al. Efficacy of entecavir treatment for up to 5 years in nucleos (t) ide-naïve chronic hepatitis B patients in real life. International journal of medical sciences. 2013; 10 (4): 427.
  12. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New England Journal of Medicine. 2008; 359 (23): 2442–55.
  13. Yuen M-F, Seto W-K, Fung J, Wong DK-H, Yuen JC-H, Lai C-L. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Official journal of the American College of Gastroenterology| ACG. 2011; 106 (7): 1264–71.
  14. Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, et al. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients. Clinics and research in hepatology and gastroenterology. 2018; 42 (1): 40–7.
  15. Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, et al. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. International Journal of Infectious Diseases. 2014; 28: 153–9.
  16. Chang T-T, Gish RG, De Man R, Gadano A, Sollano J, Chao Y-C, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. New England Journal of Medicine. 2006; 354 (10): 1001–10.
  17. Lai C-L, Shouval D, Lok AS, Chang T-T, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. New England Journal of Medicine. 2006; 354 (10): 1011–20.
  18. Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, et al. Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy. Clinical Gastroenterology and Hepatology. 2017; 15 (7): 1087–94.
  19. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection. Digestive Diseases and Sciences. 2015; 60 (5): 1457–64.
  20. Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3-year prospective field practice study in Germany. Digestive diseases and sciences. 2016; 61 (10): 3061–71.
  21. Gish R, Chang TT, Lai CL, De Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naive HBeAg‐positive patients with chronic hepatitis B. Journal of viral hepatitis. 2010; 17 (1): 16–22.
  22. Heathcote EJ, Marcellin P, Buti M, Gane E, Robert A, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140 (1): 132–43.
  23. Park JW, Kwak KM, Kim SE, Jang MK, Suk KT, Kim DJ, et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients. BMC gastroenterology. 2017; 17 (1): 1–9.
  24. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011; 54 (2): 443–51.
  25. Ibragimov EhK, Abduraxmanov DT, Rozina TP, Nikulkina EN, Tanashhuk EL, Odincov AV, et al. Ehffektivnost' i bezopasnost' dlitel'noj terapii xronicheskogo gepatita V nukleozidnymi i nukleotidnymi analogami. Terapevticheskij arxiv. 2019; 91 (2): 40–7.
  26. Chen C-H, Hung C-H, Wang J-H, Lu S-N, Hu T-H, Lee C-M. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clinical Microbiology and Infection. 2018; 24 (9): 997–1003.
  27. Liu J, Li T, Zhang L, Xu A. The role of hepatitis B surface antigen in nucleos (t) ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology. 2019; 70 (3): 1045–55.